SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Common ADHD medication prescribed in childhood may protect against risk of psychosis - 2Moving Wedding Objections for Paramount Functions
- 3Radiate brilliantly: The 5 Precious stone Rings to Purchase in 2024
- 4Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 510 times the sky amazed us in 2025
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- Find the Mysteries of Effective Objective Setting: Transforming Dreams into Feasible Targets
- Somaliland denies trading recognition with Israel for accepting Gazans
- I’m a neuroscientist who taught rats to drive − their joy suggests how anticipating fun can enrich human life
- Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC
- Involved Vehicles for Seniors: Track down the Best Picks for Solace and Unwavering quality
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- NASA Artemis 2 astronauts to make historic moon flyby today. Here's what to expect hour by hour (timeline)
- Ukrainian drones hit all three Baltic States − did Russia redirect them?
